Simona Cocos of Zentiva Romania explains how the affiliate has developed since its separation from Sanofi and how recent acquisitions have impacted local operations. She shares how the extremely diversified portfolio is a key strength and how new ventures in consumer health are helping boost performance. Cocos adds that continued investment of over EUR 19 million has made the affiliate a market leader in Romania but also an international production hub winning tenders in Western Europe.
The current form of clawback is profoundly incorrect, as it is damaging to patients and the Romanian drug industry. Furthermore, it endangers the sustainability and existence of the generics industry
